>Year 2002, Issue 4
Gutiérrez SC, Arias FJC, Montes HJM, González YJM,Vega PJ
Modifications in intestinal secretion and absorption and in glycemia by different doses of the somatostatin analogue (SMS 201995)
Cir Gen 2002; 24 (4)
PDF: 4. Kb.
Objective: To identify the minimal dose of the somatostatin analogue SMS 201 995 with effect on intestinal secretion and absorption and on glycemia.
Setting: School of Medicine.
Design: Experimental study in laboratory animals, prospective, with control group.
Statistical analysis: The mean, variance, and standard deviation of each variable were obtained. Student’s t test was used.
Material and methods: A modified Tryri Vela loop was used in five mongrel dogs, the 6-hour intestinal liquid was collected every 24 hours during 10 days. Three study groups were formed. I. Basal. II. Subcutaneous administration of 1 µg/kg of the analogue, and III. Subcutaneous administration of 5 µg/kg of the analogue. The volume, protein and electrolyte contents were measured in the collected intestinal liquid; from the 150 samples, 44 were discarded for the animal had partially ripped the ileostomy sac and collection was incomplete. Glycemia was determined before and 30 min after analogue administration.
Results: The loss of volume and protein content decreased more than 50% in groups II and III (p ‹ 0.01), without difference between these two groups (p › 0.05). Decrease in electrolyte loss was smaller; the difference between group I and groups II and III was significant (p ‹ 0.05), but not between the two latter groups (p › 0.05). Glycemia increased more than 25% in groups II and III (p ‹ 0.05); no difference was observed between groups II and III (p › 0.05).
Conclusion: The SMS 201 995 analogue reduced the intestinal loss of water, proteins, and electrolytes, besides producing hyperglycemia. There was no difference between the 1 and 5 µg/kg dose of the analogue.
||Somatostatin, analogues, intestinal secretion and absorption, glucose.
Krulich L, Dhariwall AP, McCann SM. Stimulatory and inhibitory effects of purified hypotalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783-90.
Hellman B, Lernmark A. Inhibition of the in vitro secretion of insulin by an extract of pancreatic alfa-cells. Endocrinology 1969; 84: 1484-8.
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-501.
Gutiérrrez-Samperio C, Gómez Gómez J, Montes Hernández JM, González Yáñez JM, Arias Frausto JC. Efecto del análogo de la somatostatina (SMS 201 995) sobre la circulación esplácnica. Cir Ciruj 1996; 64: 157-61.
Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with Willebrand’s disease. Br J Haematol 2000; 108: 524-7.
Unger RH. Somatostatin. N Engl J Med 1977; 296: 998-1000.
Veber DF, Holly FW, Nutt RF, Bergstrand SJ, Brady SF, Hirschmann R et al. Highly active cyclic and byciclic somatostatin analogues of reduced ring size. Nature 1979; 280: 512-4.
Camilleri M, Effects of somatostatin analogues in human gastrointestinal motility. Digestion 1996; 57(Suppl 1): 90-2.
Visser-Wissellaar HA, Hofland LJ, van Uffelen CJ, van Koetsveld PM, Lamberts SW. Somatostatin receptors manipulation. Digestion 1996; 57(Suppl 1): 7-10.
Raynor K, Coy DC, Reisine T. Analogues of somatostatin bind selectively to brain somatostatin receptor subtypes. J Neurochem 1992; 59: 1241-50.
Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5.
Wyrnnick D, Bloom SR. Clinical review 23: The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991; 73: 1-3.
Miranda-Ruiz R, Zárate Treviño A. Utilidad terapéutica de somatostatina sintética de acción prolongada en enfermedades gastrointestinales. Rev Gastroenterol Mex 1991; 56: 1.
Castañon González JA, Miranda Ruiz R, Arias E, Fuentes Pintado E, Zarate A. El análogo de la somatostatina SMS (201 995) como tratamiento adyuvante en pacientes con fístulas externas del aparato digestivo. Gac Med Mex 1992; 128: 285-8.
Guide for the care and use of laboratory animals. US Department Health and Human Sciences. Public Health Service. National Institutes of Health, 1985.
Marckowits J. Cirugía experimental y fisiología quirúrgica. 2ª ed. México: Interamericana; 1967. p187.
Gutiérrez Samperio C. El modelo experimental en cirugía. Perspectiva histórica. Cir Gen 2000; 22: 272-8.
Dawson-Saunders B, Trapp RG. Bioestadística médica. México: El Manual Moderno; 1993. p. 119.
Smith PA, Sellers LA, Humphrey PP. Somatostatin activates two types of inwardly rectifyng K+ channels in MIN -6 cells. J Physiol 2001; 532(p +1): 127-42.
Janecka A, Zubrzycka M, Janecki T. Somatostatin analogs. J Pept Res 2001; 58: 91-107.
Gjourp I, Roikjaer O, Andersen B, Burcharth F, Hovendal C, Pedersen. SA et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet 1992; 175: 397-400.
Juárez Corona D, Butron López FG, Sentíes Carvajal S, Flores Gómez S, Nangullasmu Avendaño A, Hernández Cardona FJ. Efectividad terapéutica del octreotide (análogo de la somatostatina) en pacientes con problemas quirúrgicos gastrointestinales. Cir Gen 2000; 22: 221-5.
Guiro FF, Bertolini G, Salas JV. Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treatment with SMS 201-995: experimental protocol. Surg Today 1999; 29: 419-30.
Strowski MZ, Parmar RM, Blake AD, Shaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000; 141: 111-7.
Straub SG, Cosgrove KE, Ammala C, Shepherd RM, O´Brien RE, Barnes PD, et al. Hyperinsulinism of infancy: the regulated release of insulin by K ATP channel-independent pathways. Diabetes 2001; 50: 329-39.
Rocheville M, Lange DC, Kumar U, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterolo-oligomers with enhanced functional activity. Science 2000; 288: 154-7.
Hatzoglou A, Bakogeorgou E, Papakonstanti E, Stournaras C, Emmanouel DS. Castanas E. Identification and characterization of opioid and somatostatin binding sites in opossum kidney. (OK) cell line and their effect on growth. J Cell Biochem 1996; 63: 410-21.
Poussen HH, de Herder WW, Bonjer HJ, Wauters CC, Krenning EP, Lamberts SW. An unusual case of multiple endocrine neoplasia type 1 and the role of 111 in pentetreotide scintigraphy. Neth J Med 1996; 49: 112-5.
Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. J Nucl Med 1996; 37: 916-22.
Di Leo A, Bajetta E, Ferravi L, Biganzoli L, Mariani L, Carnaghi C et al. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Cancer 1996; 78: 35-42.
Moldovan S, Brunicardi FC. Endocrine pancreas: summary of observations generated by surgical fellows. World J Surg 2001; 25: 468-73.
Nakamura T, Kudoh K, Takebe K, Imamura K, Terada A, Kikuchi H et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steathorrhea in healthy subjects. Intern Med 1994; 33: 593-6.
>Year 2002, Issue 4